Biohaven Ltd.’s recently made public that its Chief Executive Officer Coric Vlad acquired Company’s shares for reported $0.41 million on Oct 31. In the deal valued at $15.97 per share,25,800 shares were bought. As a result of this transaction, Coric Vlad now holds 1,543,394 shares worth roughly $ 23.43 million.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Then, Coric Vlad bought 100,000 shares, generating $1,482,420 in total proceeds. Upon buying the shares at $14.82, the Chief Executive Officer now owns 109,565 shares.
Before that, Coric Vlad bought 41,930 shares. Biohaven Ltd. shares valued at $623,352 were divested by the Chief Executive Officer at a price of $14.87 per share. As a result of the transaction, Coric Vlad now holds 1,517,594 shares, worth roughly $23.04 million.
SVB Securities initiated its Biohaven Ltd. [BHVN] rating to an Outperform in a research note published On Friday, January 24, 2023; the price target was $24. A number of analysts have revised their coverage, including JP Morgan’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. BTIG Research began covering BHVN with “Buy” recommendation on December 02, 2022. Cantor Fitzgerald revised its rating on October 26, 2022. It rated BHVN as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of BHVN
On Friday, Biohaven Ltd. [NYSE:BHVN] saw its stock fall -2.63% to $15.18. Over the last five days, the stock has lost -7.10%. Biohaven Ltd. shares have risen nearly 9.37% since the year began. A total of 0.68 million shares were traded, compared to the trading of 0.91 million shares in the previous session.
Levels Of Support And Resistance For BHVN Stock
The 24-hour chart illustrates a support level at 14.96, which if violated will result in even more drops to 14.75. On the upside, there is a resistance level at 15.49. A further resistance level may holdings at 15.81. The Relative Strength Index (RSI) on the 14-day chart is 38.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.56, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.57%. Stochastics %K at 9.01% indicates the stock is a buying.
How much short interest is there in Biohaven Ltd.?
A steep rise in short interest was recorded in Biohaven Ltd. stocks on Jan 30, 2023, dropping by -0.79 million shares to a total of 3.39 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 4.18 million shares. There was a decline of -23.3%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.24% of the overall stock float, the days-to-cover ratio (short ratio) fell to 3.22.
Biohaven Ltd. [BHVN] – Who Are The Largest Shareholders?
In filings from 1919 Investment Counsel LLC, it is revealed that the company now owns 5,618,948 shares, or roughly 8.24% of the outstanding BHVN shares. Additionally, SSgA Funds Management, Inc. increased 877.78% of its stake after which the total value it holdings stand at $87,643,374, while Janus Henderson Investors US LLC added 811.05% of its stake to hold $87.1 million in the firm. Over the last quarter, Suvretta Capital Management LLC purchased 3,787,307 shares of Biohaven Ltd., while BlackRock Fund Advisors bought 3,715,973 shares. At present, RP Management LLC is holding 2,936,507 shares valued at $56.06 million. Armistice Capital LLC owned 2,724,000 shares of the company at the time of its most recent 13F filing, worth $52.0 million.
The most recent change occurred on October 12, 2022 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $23 price target.